Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on January 4, 2024.

Summary

• Lilly Endowment Inc. sold 13,688 shares of Eli Lilly & Co. common stock at a weighted average price of $630.238 per share on January 4, 2024.
• Additionally, Lilly Endowment Inc. sold 700 shares of Eli Lilly & Co. common stock at a weighted average price of $631.068 per share on the same day.
• The total number of shares sold was 14,388.
• Following these transactions, Lilly Endowment Inc. beneficially owns 99,754,422 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale, with no indication of positive or negative sentiment.

Management Comments

• Peter A. Buck, Vice President for Investments and Grants Administration, signed the Form 4 on behalf of Lilly Endowment Inc.

Industry Context

This is a routine filing related to a significant shareholder's transactions in the company's stock. Such filings are common and provide transparency into insider trading activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies.
• The transactions are typical for large institutional investors managing their portfolios.
• The sale of shares by Lilly Endowment Inc. is not unusual given their large holdings in Eli Lilly & Co.

Stakeholder Impact

• The sale of shares may have a minor impact on the stock price, but is unlikely to have a significant effect on other stakeholders.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, Form 4